Paraneoplastic neuromyelitis optica spectrum disorder associated with malignant melanoma: A case report

Toshiki Morimoto1,2 | Shotaro Hayashida3 | Kei Yamasaki2 | Yosuke Sasahara1,2 | Tsutomu Takaki1,2 | Kazuhiro Yatera2

1Department of Internal Medicine, Kyushu Rosai Hospital, Fukuoka, Japan
2Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Japan
3Department of Neurology, Kyushu Rosai Hospital, Fukuoka, Japan

Correspondence
Kei Yamasaki, Department of Respiratory Medicine, University of Occupational and Environmental Health Japan, 1-1 Iseigaoka, Kitakyushu, Fukuoka 807-8555, Japan.
Email: yamasaki@med.uoeh-u.ac.jp

Abstract
Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune demyelinating diseases involving the central nervous system (CNS), including optic neuritis and transverse myelitis. NMOSD has been associated with anti-aquaporin-4 (AQP4) antibodies.1 The prevalence of anti-AQP4 antibody-positive NMOSD is 3.42 in 100 000 individuals in Japan.2 The mean age of onset is 30–40 years, but elderly patients are often seen.3 Several reports have associated the CNS with malignant melanoma, such as in cerebellar degeneration,4 limbic encephalitis,5 Guillain-Barré syndrome,6 and chronic inflammatory demyelinating polyneuropathy,7 but there are few reports of paraneoplastic neurological syndrome (PNS) associated with malignant melanoma. We present a 65-year-old Japanese female patient with a rare case of anti-AQP4 antibody-positive NMOSD complicated with malignant melanoma.

KEYWORDS
anti-aquaporin-4 antibody, malignant melanoma, neuromyelitis optica spectrum disorders, paraneoplastic neurological syndrome

INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune demyelinating diseases involving the central nervous system (CNS), including optic neuritis and transverse myelitis. NMOSD has been associated with anti-aquaporin-4 (AQP4) antibodies.1 The prevalence of anti-AQP4 antibody-positive NMOSD is 3.42 in 100 000 individuals in Japan.2 The mean age of onset is 30–40 years, but elderly patients are often seen.3 Several reports have associated the CNS with malignant melanoma, such as in cerebellar degeneration,4 limbic encephalitis,5 Guillain-Barré syndrome,6 and chronic inflammatory demyelinating polyneuropathy,7 but there are few reports of paraneoplastic neurological syndrome (PNS) associated with malignant melanoma. We present a 65-year-old Japanese female patient with a rare case of anti-AQP4 antibody-positive NMOSD complicated with malignant melanoma.

CASE REPORT
A 61-year-old Japanese woman with no specific medical, smoking, or family history was admitted to our hospital because of palsy of the left upper extremity and bilateral lower extremities and urinary disorder. Brain magnetic resonance imaging (MRI) revealed multiple hyperintense T2 lesions (Figure 1). Spinal MRI showed signal abnormalities from the medulla oblongata and the postrema to the 10th thoracic level. Serum anti-AQP4 antibodies were positive; therefore, she was diagnosed with NMOSD.8 She had no complications of collagen vascular disease and no findings of malignancies on abdominal computed tomography (CT). Improvement of manual muscle testing of the left upper extremity (from 3 to 4) and bilateral lower extremities (from 0 to 3) was achieved via combined treatment with high-dose intravenous methylprednisolone (1 g/day for three days) and immunoadsorption therapy for five cycles, but neither the total sensory disturbance below the fourth thoracic level nor urinary disturbance improved. After these treatments, combined treatment with oral prednisolone and an immunosuppressant was subsequently continued at an initial dose of 40 mg/day with 2 mg of tacrolimus, tapered down to 10 mg, resulting in a relapse-free status for four years.

Four years after the onset of NMOSD, she experienced anorexia, nausea, general fatigue, and dry cough two weeks before admission to our hospital. Physical examination on admission revealed the following: height, 154.0 cm; bodyweight, 61.5 kg; body temperature, 37.0°C; heart rate,
120 bpm; blood pressure, 151/84 mmHg; and oxygen saturation, 94% (nasal oxygen 3 L/min, at rest). Right respiratory sounds were attenuated on chest auscultation, but there was no exacerbation of neurological findings. Laboratory results (Table 1) showed a high titer of cancer antigen 125 (246.3 U/ml) and neuron-specific enolase (43.9 ng/ml). Chest and abdominal CT findings revealed a 110 mm pulmonary mass in the right lower lobe, multiple irregular pulmonary nodules, right pleural effusion, and multiple liver, skin, left adrenal, right renal, and bone metastases (Figure 2). Brain and spinal MRI revealed no metastases or new NMOSD lesions. Cerebrospinal fluid findings including cytology were normal (Table 1). Cytological findings of the right pleural effusion revealed no evidence of malignancy. There were several metastatic lesions of malignant melanoma in the chest and abdomen in our patient; thus, the primary lesion was unclear. A biopsy was performed of the metastatic lesions in the right chest and liver. Immunocytochemistry of skin and liver needle biopsies (Figure 3(a)–(d)) revealed tumor cells positive for S-100, HMB45, and SOX10, and negative results for BRAF, which indicated a diagnosis of malignant melanoma. The PD-L1 tumor proportion score was less than 1% (Figure 3(e)). Malignant disease was diagnosed four years after the onset of encephalomyelitis (within five years) in the present patient, fulfilling the criteria for classical PNS. Therefore, she was diagnosed with paraneoplastic NMOSD associated with malignant melanoma. At that time, serum anti-AQP4 antibodies were still positive. Serum onconeural antibodies, such as anti-Hu, SOX1, CV2, Yo, Ri, MOG, recoverin, titin, ZIC4, GAD65 were all negative.

Combined systemic chemotherapy with carboplatin (area under the concentration-time curve, 5), paclitaxel (200 mg/m²), and bevacizumab (15 mg/kg) was administered as first-line treatment for malignant melanoma, but disease progression was observed after two courses. As such, nivolumab (240 mg) was administered as second-line treatment. However, pulmonary and liver metastases progressed after two courses of nivolumab with worsening of her respiratory condition and performance status. She died 120 days after the diagnosis of malignant melanoma.

DISCUSSION

We present a rare case of paraneoplastic anti-AQP4 antibody-positive NMOSD associated with malignant melanoma that completely fulfilled the diagnostic criteria for both NMOSD and PNS. Our patient was diagnosed with anti-AQP4 antibody-positive NMOSD four years before the diagnosis of malignant melanoma.

The prevalence of paraneoplastic neuromyelitis optica (NMO) with positive results for anti-AQP4 antibodies is 3%–5% in NMO patients and 0.017% in patients suspected to have PNS.10,11 Some cases were also identified as paraneoplastic NMOSD, including various cancers.10,12–18 Only one case of malignant melanoma complicated with anti-AQP4 antibody-positive NMOSD has been reported.19 However, that patient developed NMOSD while under interferon treatment, and the authors ruled out paraneoplastic NMOSD due to no recurrence of melanoma and a 48-month interval between melanoma excision and the development of NMOSD.19 In contrast, our patient developed malignant melanoma after NMOSD. Classical PNS is defined as “a classical syndrome and cancer that develops within five years of the diagnosis of the neurological disorder;” hence, only our patient fulfilled the criteria for PNS.9

“Paraneoplastic NMOSD” has, in part, been controversial because excluding the possibility of accidental complications might be difficult. Anti-AQP4 antibodies are thought to be the putative mechanism for the development of
### Laboratory data on admission

| <Blood cell counts> | T-bil | 0.55 mg/dl | CYFRA21-1 | 1.7 ng/ml |
|--------------------|-------|-------------|-----------|-----------|
| WBC 9200 /μl       | AST   | 54 IU/L     | Pro-GRP   | 44.0 pg/ml|
| Neutrophils 88.8 % | ALT   | 52 IU/L     | CA125     | 246.3 U/ml|
| Lymphocytes 5.0 %  | LDH   | 816 IU/L    | SLX       | 30 U/ml   |
| Eosinophils 0.2 %  | BUN   | 9.0 mg/dl   | NSE       | 43.9 ng/ml|
| Monocytes 5.7 %    | Cre   | 0.55 mg/dl  | AFP       | 4.5 ng/ml |
| RBC 4.25 × 10^6 /μl| Na    | 134 mEq/L   | PIVKA-II  | 26.94 mAU/ml|
| Hb 13.7 g/dl       | K     | 4.2 mEq/L   | sIL-2R    | 771 U/ml  |
| Ht 40.7 %          | Cl    | 101 mEq/L   | <cerebrospinal fluid> |
| Platelets 22.8 × 10^4 /μl | Glucose | 107 mg/dl | Cell counts | 1 /μl |
| <Blood chemistry>  | HbA1c | 5.4 %       | Protein   | 16 mg/dl  |
| TP 5.8 g/dl        | CRP   | 0.63 mg/dl  | Cytology  | No malignancy |
| Alb 3.4 g/dl       | CEA   | 2.5 ng/ml   | IgG index | 0.47      |
|                   | CA19-9| 5.1 U/ml    | Oligoclonal bands | Absent |

Abbreviations: AFP, α-fetoprotein; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CA125, cancer antigen 125; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; CYFRA 21–1, cytokeratin fragment 21–1; Hb, hemoglobin; Ht, hematocrit; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; PIVKA-II, protein induced by vitamin K absence-II; Pro-GRP, Pro-gastrin-releasing peptide; RBC, red blood cell; sIL-2R, soluble interleukin-2 receptor; SLX, sialyl Lewis X-α antigen; T-bil, total bilirubin; TP, total protein; WBC, white blood cell; γ-GTP, gamma-glutamyl transferase.

**FIGURE 2** Chest and abdominal computed tomography (CT) scan of the patient. A 110 mm mass was seen in the right lower lobe (a), and multiple irregular pulmonary nodules, right pleural effusion (b), multiple liver metastases, and multiple skin metastases (c) were observed.
NMOSD when cancer cells are positive for anti-AQP4 antibodies.\textsuperscript{10} A case report detailing the development of anti-AQP4 antibody-positive NMOSD immediately after the relapse of stomach cancer might support this concept, although there was no immunohistochemical confirmation of AQP4 in cancer cells.\textsuperscript{18} Furthermore, paraneoplastic
NMO/MSD has previously been reported in a patient with adenocarcinoma of the esophagogastric (EG) junction that exhibited immunoreactivity to AQP4 and an elevated serum AQP4-IgG level that turned to be undetectable after surgical resection of the tumor, suggestive of an induction of anti-AQP4 antibodies by the tumor cells that lead to NNMOSD. In our patient, although the onset of NMO/MSD could be coincidental, it was also speculated that occult malignant melanoma mediates the detailed causal relationship between NMO/MSD and malignant melanoma mediated by anti-AQP4 antibodies remains unknown.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

ORCID
Kei Yamasaki https://orcid.org/0000-0003-1876-3287

REFERENCES
1. Lennon VA, Kryzer TJ, Pittcock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7.
2. Miyamoto K, Fujihara K, Kira JI, Kuriyama N, Matsu M, Tamakoshi A, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89:667–8.
3. Nagaiishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Masui M, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011;82:1360–4.
4. Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol. 2013;256:94–6.
5. Bequart C, Ryckewaert G, Desmedt E, Defebvre L, Le Rhun E, Mortier L. Limbic encephalitis: a new paraneoplastic auto-immune manifestation associated with metastatic melanoma? Ann Dermatol Venereol. 2013;140:278–81,[in French].
6. Kraft Rovere R, Pires de Souza ME, Fernanda Hilgert S, Rodrigues Chamse Ddine Y, Silva de Lima A. Melanoma metastasis to the gastric mucosa preceded by Guillain–Barré as a paraneoplastic syndrome. Gastrointest Cancer Res. 2013;6:150–1.
7. Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996;46:822–4.
8. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chisin T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.
9. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.
10. Pittcock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008;65:629–32.
11. Sepúlveda M, Sola-Valls N, Escudero D, Rojc B, Barón M, Hernández-Echebarria L, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018;24:1753–9.
12. Mueller S, Dubal DB, Josephson SA. A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody. Nat Clin Pract Neurol. 2008;4:284–8.
13. De Santis G, Caniatti L, De Vito A, De Gennaro R, Graniere E, Tola MR. A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci. 2009;30:397–400.
14. Al-Harbi T, Al-Sarawi A, Binfalih M, Dermime S. Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoma. Hematol Oncol Stem Cell Ther. 2014;7:116–9.
15. Yang HK, Woo SJ, Park WY, Hwang JM. Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma. BMC Ophthalm. 2014;14:106.
16. Deuel LM, Bunch ME. A case of paraneoplastic neuromyelitis optica associated with small cell lung carcinoma. J Neuroimmunol. 2018;316:130–2.
17. Kon T, Ueno T, Suzuki C, Nunomura J, Igarashi S, Sato T, et al. Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer. J Neuroimmunol. 2017;309:38–40.
18. Takewaki D, Kasai T, Itoh K, Shiga K, Tokui M, Tanaka A, et al. Case of neuromyelitis optica with recurrent stomach carcinoma. Clin Exp Neuroimmunol. 2017;8:327–30.
19. Sudo A, Chihara N, Takenaka Y, Nakamura T, Ueda T, Sekiguchi K, et al. Paraneoplastic NMOSD associated with EG junction adeno-carcinoma expressing unprotected AQP4. Neurol Neuroimmunol Neuroinflamm. 2018;5(9):e482.
20. Lebrun C, Debouverie M, Vermeersch P, Clavelou P, Rumbach L, de Seze J, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;14:399–405.

How to cite this article: Morimoto T, Hayashida S, Yamasaki K, Sasahara Y, Takaki T, Yatera K. Paraneoplastic neuromyelitis optica spectrum disorder associated with malignant melanoma: A case report. Thorac Cancer. 2021;12:1775–1779, https://doi.org/10.1111/1759-7714.13965